Keravision to raise $48 million in offering:
This article was originally published in Clinica
Keravision, which has developed the Intacs corneal ring implant to treat vision disorders, plans to raise around $48 million net from an offering of four million shares at $13 each. The Fremont, California-based company will use the proceeds for the launch and marketing of Intacs in the US, where it has been cleared by the FDA for the treatment of mild myopia. The company also intends to continue development and clinical testing of further products based on its technology.
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.